Daré Bioscience Inc. (DARE)
2.91
0.01 (0.34%)
At close: Apr 02, 2025, 3:58 PM
2.90
-0.34%
After-hours: Apr 02, 2025, 04:05 PM EDT
0.34% (1D)
| Bid | 2.71 |
| Market Cap | 25.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.58 |
| PE Ratio (ttm) | -5.02 |
| Forward PE | -1.62 |
| Analyst | Buy |
| Ask | 2.99 |
| Volume | 7,304 |
| Avg. Volume (20D) | 23,960 |
| Open | 2.95 |
| Previous Close | 2.90 |
| Day's Range | 2.91 - 2.99 |
| 52-Week Range | 2.67 - 7.56 |
| Beta | 1.38 |
About DARE
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its produc...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 10, 2014
Employees 23
Stock Exchange NASDAQ
Ticker Symbol DARE
Website https://www.darebioscience.com
Analyst Forecast
According to 4 analyst ratings, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 346.74% from the latest price.
Stock ForecastsEarnings Surprise
Daré Bioscience has released their quartely earnings
on Mar 31, 2025:
7 months ago
+20%
Dare Bioscience shares are trading higher after th...
Unlock content with
Pro Subscription
7 months ago
+3.24%
Dare Bioscience shares are trading higher. The company reported Q2 financial results.
